This is a double-blind, pilot study with 20 subjects to determine the tolerability and efficacy of topical AFX 5931 in the treatment of mild to moderate hand dermatitis. Subjects are screened up to 30 days before the baseline visit. Subjects who meet the eligibility criteria may qualify for the study. Subjects will be randomized in a 3:1 ratio to receive either the active or vehicle medication. 15 subjects will receive the active, therapeutic product and 5 subjects will receive the inactive, vehicle product.

开始日期2018-09-18

申办/合作机构

Center For Clinical & Cosmetic Research

[+1]

100 项与 AFX-5931 相关的临床结果

登录后查看更多信息

100 项与 AFX-5931 相关的转化医学

登录后查看更多信息

100 项与 AFX-5931 相关的专利（医药）

登录后查看更多信息

项与 AFX-5931 相关的文献（医药）

Journal of cutaneous medicine and surgery

A Review of Existing and New Treatments for the Management of Hand Eczema.

Review

作者: Ho, Jessica S S ; Molin, Sonja

Hand eczema is a chronic condition that affects an estimated 14.5% of the general population. It has severe quality of life ramifications in those that struggle with it, including days missed from work or school, productivity loss and impaired work functioning. For years, the standard of care included topical moisturizing creams, topical steroids and more recently systemic agents. As new therapeutic targets emerge and recent advances are being developed, it is now more possible than ever that hand eczema can be managed via the underlying mechanisms. A review of the literature was conducted to identify current treatment options for hand eczema and chronic hand eczema. The terms 'hand eczema', 'hand dermatitis' were used to search PubMed, CENTRAL and Embase. To identify new therapies still undergoing investigation, we used the terms 'hand eczema', 'hand dermatitis', 'atopic dermatitis', and 'vesicular eczema of hands and/or feet' to search Clinicaltrials.gov for all studies until December 2022. There were 56 ongoing clinical trials identified for pharmacological treatments for hand eczema on Clinicaltrials.gov from 2000 - 2022, with 16 that are new or ongoing. These included studies for dupilumab, ruxolitinib, delgocitinib (LEO124249), gusacitinib (ASN002), AFX 5931, and roflumilast (ARQ-252). Two major classes of drugs emerging for the treatment of hand eczema include IL-4/IL-13 inhibitors and JAK inhibitors. With the increase in efficacy seen with these new drugs, we are also noting improved adverse effect profiles, making them attractive options to add to a clinician's management toolbox for patients with hand eczema.

100 项与 AFX-5931 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
湿疹	临床2期	-	Afecta Pharmaceuticals, Inc.	-
糖尿病性视网膜病变	临床1期	美国	-	2021-03-23
湿疹	临床前	美国	-	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03703895 (CTgov)	临床4期	手皮肤病	20	Topical AFX5931 (Active Comparator)	簾餘淵餘齋網簾齋淵鹹(鑰網鹹衊觸蓋襯廠夢簾) = 積鬱鏇糧願繭壓製衊網糧襯醖鬱築繭窪顧夢築 (蓋餘憲網廠鹹築網鬱壓, 構鏇遞構獵艱範繭簾範 ~ 醖獵憲遞鏇築艱鏇餘餘) 更多	-	2022-11-23
				Topical Placebo (Placebo Comparator)	簾餘淵餘齋網簾齋淵鹹(鑰網鹹衊觸蓋襯廠夢簾) = 簾齋衊願鑰襯積範艱窪糧襯醖鬱築繭窪顧夢築 (蓋餘憲網廠鹹築網鬱壓, 繭膚鬱鹹糧簾襯積築蓋 ~ 蓋窪製顧獵夢艱製憲夢) 更多